Rhythm(US:RYTM)2026-02-26 14:02Financial Data and Key Metrics Changes - Revenue from sales of IMCIVREE was $57.3 million for Q4 2025, representing a quarter-over-quarter increase of 12% and $194.8 million for the full year, an increase of approximately 50% from 2024 [30][31] - Gross to net for U.S. sales was approximately 84.6%, generally in line with previous quarters [33] - GAAP EPS for Q4 2025 was a net loss per basic and diluted share of $0.73, including $0.02 per share from accrued dividends on convertible preferred stock [36] Business Line Data and Key Metrics Changes - In Q4 2025, $39 million, or 68% of product revenue, was generated in the United States, and $18.3 million, or 32% of product revenue, was generated outside the United States [31] - The volume of vials shipped to specialty pharmacy in the U.S. was approximately 1.7 million greater than the vials dispensed to patients, resulting in a negative $1.3 million inventory swing from Q3 to Q4 [31][32] - The company expanded its sales force from 16 to 42 to prepare for the Acquired Hypothalamic Obesity launch [19] Market Data and Key Metrics Changes - The company reported a steady growth in prescriptions for BBS as teams focused on educating healthcare providers and securing reimbursement approvals [18] - The estimated prevalence of Acquired Hypothalamic Obesity in the U.S. is 10,000, representing a significant opportunity for the company [19] Company Strategy and Development Direction - The company plans to initiate the Phase 3 HO study by year-end 2026, following a constructive FDA meeting confirming readiness to move forward [13] - The company is preparing for multiple opportunities in Europe and Japan, with a higher per capita prevalence of acquired HO than the U.S. [27] - The company aims to establish reimbursement for acquired HO in Europe on a country-by-country basis, similar to previous efforts for POMC/LEPR and BBS [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of the BBS opportunity and the expected launch of Acquired Hypothalamic Obesity therapy [6][19] - The management highlighted the importance of early intervention for patients with hypothalamic obesity, suggesting that guidelines may evolve to allow earlier treatment [46] - The company anticipates a potential pull forward of revenue from Q4 into Q1 due to inventory dynamics [55] Other Important Information - The company ended 2025 with approximately $389 million in cash equivalents and short-term investments, expected to fund operations for at least 24 months [36] - Non-GAAP operating expenses for 2026 are anticipated to be approximately $385 million-$415 million, reflecting a year-over-year increase driven by clinical program success [39][40] Q&A Session Summary Question: Update on bivamelagon Phase 3 trial - Management confirmed that the trial will largely mimic the Phase 3 design of setmelanotide, with no specific changes to enrollment criteria [43] Question: Guidelines for hypothalamic obesity treatment - Management indicated that while current guidelines suggest a six-month wait post-surgery, feedback suggests earlier intervention may be beneficial [46] Question: Update on PWS study - Management stated that they are on track for a mid-year update and are looking for a minimum of 5% BMI change as a goal [50][52] Question: IMCIVREE sales trends - Management noted potential dampening of sales in Q1 due to inventory pull forward from Q4 [54] Question: EMANATE study substudies - Management explained that POMC heads are expected to be the most likely to be positive based on prior assays and patient enrollment [59] Question: Dosing for bivamelagon Phase 3 trial - Management confirmed that dosing will escalate from 200 mg to a target of 600 mg [72] Question: Opportunity in Japan - Management estimated the prevalence of acquired HO in Japan to be between 5,000 and 8,000 patients, with plans for a launch within 12 months [82]